Eli Lilly and Company
$ 1042.15
-1.55%
24 Feb - close price
- Market Cap 998,600,475,000 USD
- Current Price $ 1042.15
- High / Low $ 1058.90 / 1024.08
- Stock P/E 46.08
- Book Value 29.66
- EPS 22.97
- Next Earning Report -
- Dividend Per Share $6.00
- Dividend Yield 0.59 %
- Next Dividend Date 2026-03-10
- ROA 0.19 %
- ROE 1.01 %
- 52 Week High 1132.06
- 52 Week Low 620.46
About
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Analyst Target Price
$1212.82
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-02-06 | 2024-10-30 | 2024-08-08 | 2024-04-30 | 2024-02-06 | 2023-11-02 | 2023-08-08 | 2023-04-27 |
| Reported EPS | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | 0.1 | 2.11 | 1.62 |
| Estimated EPS | 7.17 | 6.37 | 5.59 | 3.54 | 5.0668 | 1.47 | 2.6 | 2.46 | 2.22 | -0.13 | 1.98 | 1.73 |
| Surprise | 0.37 | 0.65 | 0.72 | -0.2 | 0.2532 | -0.29 | 1.32 | 0.12 | 0.27 | 0.23 | 0.13 | -0.11 |
| Surprise Percentage | 5.1604% | 10.2041% | 12.8801% | -5.6497% | 4.9972% | -19.7279% | 50.7692% | 4.878% | 12.1622% | 176.9231% | 6.5657% | -6.3584% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-10 | 2024-06-10 | 2024-03-08 | 2023-12-08 |
| Amount | $1.73 | $1.5 | $1.5 | $1.5 | $1.5 | $1.3 | $1.3 | $1.3 | $1.3 | $1.13 |
Next Dividend Records
| Dividend per share (year): | $6.00 |
| Dividend Yield | 0.59% |
| Next Dividend Date | 2026-03-10 |
| Ex-Dividend Date | 2026-02-13 |
Recent News: LLY
2026-02-24 19:29:40
Kroger has launched GLP-1 weight management savings programs, allowing customers to fill any provider's GLP-1 prescription at Kroger pharmacies with access to manufacturer discounts and insurance guidance. The initiative also integrates nutritional support with virtual dietitian appointments and the OptUP program, addressing the growing demand for GLP-1 drugs and competition in the medication-supported weight management market.
2026-02-24 15:49:36
AbbVie plans to invest $380 million in two new active pharmaceutical ingredient manufacturing facilities at its North Chicago campus, creating 300 new jobs. These facilities, incorporating advanced manufacturing and AI, are set to produce next-generation neuroscience and obesity drugs, with construction starting in spring 2026 and operations by 2029. This investment is part of AbbVie's larger $100 billion commitment to strengthen its U.S. manufacturing and R&D capabilities over the next decade.
2026-02-24 08:50:51
Pfizer has secured exclusive commercialization rights in China for Sciwind Biosciences' obesity therapy, ecnoglutide, potentially valued at up to $495 million. This move strengthens Pfizer's position in China's rapidly expanding weight-loss drug market, where it aims to compete with other global and local pharmaceutical companies. This collaboration is part of Pfizer's broader strategy to find new revenue streams and build new growth trajectories through external partnerships and acquisitions.
/Lilly(Eli)%20%26%20Co%20logo%20on%20building-by%20Michael%20Vi%20via%20Shutterstock.jpg)
2026-02-24 06:04:50
Eli Lilly (LLY) stock has largely outperformed the S&P 500 over the past 52 weeks, despite a slight underperformance year-to-date and over the last three months. The company's recent Q4 fiscal 2025 results showed strong revenue and EPS growth, driven by demand for Zepbound and Mounjaro, leading to a "Strong Buy" rating from analysts and a significant potential upside.
2026-02-24 05:00:15
Pfizer has entered a significant licensing agreement with Sciwind Biosciences for the diabetes treatment ecnoglutide, potentially worth $495 million. Despite declining revenue growth, Pfizer shows strong profitability margins and a stable financial position. Valuation metrics suggest the company is fairly valued with moderate buy sentiment from analysts.
2026-02-24 03:32:03
The Zacks Market Edge podcast, hosted by Tracey Ryniec, discusses "The New Magnificent Stocks to Own in 2026," moving beyond the traditional tech giants. The episode highlights five non-tech companies—MasTec, Caterpillar, Walmart, Eli Lilly, and Howmet Aerospace—that are reaching new 5-year highs and are projected to have double-digit earnings growth in 2026, despite not being considered value stocks. Investors are encouraged to consider these companies as potential high-growth opportunities.
